LIVN
LivaNova PLC
$78.50
0.00%
$4.3B
No data for this timeframe.
Vol
Market Cap$4.3B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (81%)
Insider Activity0B / 2S
Insider Net $-$232.6K
Reddit Sentiment50° Neutral
SEC Reports3
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. X0·CIK 0001639691·Prev Close $78.50
Recent Activity
Jun 15, 2026
Insider
Bianchi Francesco acquired via exercise 4,042 shares
Director
Jun 15, 2026
Insider
PODLOGAR SUSAN M surrendered for taxes 486 shares
Director @ $79.70 ($38.7K)
Jun 15, 2026
Insider
Zurbay Donald was granted 2,383 shares
Director
Jun 10, 2026
short_volume
Short Volume: LIVN — 84.8% short (0.6M / 0.7M)
Short: 600,662 | Exempt: 31,100 | TRF Vol: 708,499 | Short Ratio: 84.8% | Off-exchange volume (dark
May 6, 2026
SEC
LivaNova reported Q1 2026 revenue of $362.3M (+14.3% YoY reported, +11.1% constant-currency), beating consensus of $346.
8-K — Impact 8/10
Apr 29, 2026
SEC
LivaNova filed a definitive additional proxy soliciting material (DEFA14A) providing notice of its 2026 Annual General M
DEFA14A — Impact 2/10
Feb 25, 2026
SEC
LivaNova reported strong full-year 2025 results with double-digit revenue growth and improved margins, driven by both Ca
8-K — Impact 7/10
Price Targets
$80.60
+2.7% upside
Hold
Current $78.50
Low $67.00
Median $80.50
High $95.00
10 analysts
$67.00
$95.00
Analyst Ratings
6Strong Buy
7Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 7, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| Feb 27, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| Feb 25, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.09 | $1.06 — $1.13 | 4% YoY | 9 |
| Next Q | $1.08 ▼ -4.5% | $1.03 — $1.13 | -3% YoY | 9 |
| Current FY | $4.25 | $4.23 — $4.26 | 9% YoY | 9 |
| Next FY | $4.63 | $4.49 — $4.93 | 9% YoY | 9 |
Latest Reports
BULLISH
8-K
8/10
LivaNova reported Q1 2026 revenue of $362.3M (+14.3% YoY reported, +11.1% constant-currency), beating consensus of $346.
May 6, 2026
NEUTRAL
DEFA14A
2/10
LivaNova filed a definitive additional proxy soliciting material (DEFA14A) providing notice of its 2026 Annual General M
Apr 29, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 15, 2026 | Bianchi Francesco | M | $0.00 |
| Jun 15, 2026 | PODLOGAR SUSAN | F | $38.7K |
| Jun 15, 2026 | Zurbay Donald | A | $0.00 |
| Jun 15, 2026 | WILVER PETER | M | $0.00 |
| Jun 15, 2026 | Barry James | F | $38.7K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
15 unique insiders with 50 transactions. Net insider value: -$232.6K ($0.00 bought, $232.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | Bianchi Francesco | Director | EXERCISE | 4,042 | — | — |
| Jun 15, 2026 | PODLOGAR SUSAN M | Director | TAX W/H | 486 | $79.70 | $38.7K |
| Jun 15, 2026 | Zurbay Donald | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | WILVER PETER M | Director | EXERCISE | 4,042 | — | — |
| Jun 15, 2026 | Barry James Christopher | Director | TAX W/H | 486 | $79.70 | $38.7K |
| Jun 15, 2026 | PODLOGAR SUSAN M | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | Bianchi Francesco | Director | TAX W/H | 486 | $79.70 | $38.7K |
| Jun 15, 2026 | Barry James Christopher | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | Story Brooke | Director | TAX W/H | 486 | $79.70 | $38.7K |
| Jun 15, 2026 | Tezel Ahmet | Chief Innovation Officer | EXERCISE | 2,965 | — | — |
| Jun 15, 2026 | KOZY WILLIAM A | Director | EXERCISE | 5,681 | — | — |
| Jun 15, 2026 | Barry James Christopher | Director | EXERCISE | 4,042 | — | — |
| Jun 15, 2026 | Tezel Ahmet | Chief Innovation Officer | TAX W/H | 1,032 | $79.70 | $82.3K |
| Jun 15, 2026 | SCHERMERHORN TODD C | Director | EXERCISE | 4,042 | — | — |
| Jun 15, 2026 | SCHERMERHORN TODD C | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | Bianchi Francesco | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | Nygaard-Andersen Jette | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | SCHERMERHORN TODD C | Director | TAX W/H | 486 | $79.70 | $38.7K |
| Jun 15, 2026 | Bianchi Francesco | Director | SELL | 1,200 | $80.19 | $96.2K |
| Jun 15, 2026 | WILVER PETER M | Director | TAX W/H | 486 | $79.70 | $38.7K |
| Jun 15, 2026 | WILVER PETER M | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | PODLOGAR SUSAN M | Director | EXERCISE | 4,042 | — | — |
| Jun 15, 2026 | Enxing Seng Stacy | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | Story Brooke | Director | EXERCISE | 4,042 | — | — |
| Jun 15, 2026 | KOZY WILLIAM A | Director | TAX W/H | 682 | $79.70 | $54.4K |
| Jun 15, 2026 | KOZY WILLIAM A | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | Enxing Seng Stacy | Director | EXERCISE | 4,042 | — | — |
| Jun 15, 2026 | Enxing Seng Stacy | Director | TAX W/H | 486 | $79.70 | $38.7K |
| Jun 15, 2026 | Zurbay Donald | Director | EXERCISE | 2,560 | — | — |
| Jun 15, 2026 | Story Brooke | Director | AWARD | 2,383 | — | — |
| Jun 15, 2026 | Zurbay Donald | Director | TAX W/H | 308 | $79.70 | $24.5K |
| May 26, 2026 | Bianchi Francesco | Director | SELL | 1,800 | $75.75 | $136.3K |
| Mar 30, 2026 | Kozmina Natalia | Chief Human Resources Officer | EXERCISE | 4,259 | — | — |
| Mar 30, 2026 | Kozmina Natalia | Chief Human Resources Officer | AWARD | 9,792 | — | — |
| Mar 30, 2026 | Kozmina Natalia | Chief Human Resources Officer | TAX W/H | 1,374 | $61.27 | $84.2K |
| Mar 30, 2026 | Kozmina Natalia | Chief Human Resources Officer | AWARD | 3,264 | — | — |
| Mar 30, 2026 | Bolton Stephanie | President, Global Epilepsy | AWARD | 8,976 | — | — |
| Mar 30, 2026 | Kozmina Natalia | Chief Human Resources Officer | EXERCISE | 6,389 | — | — |
| Mar 30, 2026 | Bolton Stephanie | President, Global Epilepsy | EXERCISE | 17,815 | — | — |
| Mar 30, 2026 | Bolton Stephanie | President, Global Epilepsy | TAX W/H | 8,377 | $61.27 | $513.3K |
| Mar 30, 2026 | Bolton Stephanie | President, Global Epilepsy | EXERCISE | 457 | — | — |
| Mar 30, 2026 | Bolton Stephanie | President, Global Epilepsy | EXERCISE | 3,243 | — | — |
| Mar 30, 2026 | Bolton Stephanie | President, Global Epilepsy | AWARD | 2,992 | — | — |
| Mar 30, 2026 | Shvartsburg Alex | Chief Financial Officer | EXERCISE | 30,835 | — | — |
| Mar 30, 2026 | Shvartsburg Alex | Chief Financial Officer | AWARD | 16,321 | — | — |
| Mar 30, 2026 | Shvartsburg Alex | Chief Financial Officer | TAX W/H | 12,868 | $61.27 | $788.4K |
| Mar 30, 2026 | Shvartsburg Alex | Chief Financial Officer | EXERCISE | 914 | — | — |
| Mar 30, 2026 | Shvartsburg Alex | Chief Financial Officer | EXERCISE | 5,768 | — | — |
| Mar 30, 2026 | Poletti Franco | President, Cardiopulmonary | EXERCISE | 3,184 | — | — |
| Mar 30, 2026 | Poletti Franco | President, Cardiopulmonary | EXERCISE | 171 | — | — |
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
BULLISH
8-K
8/10
LivaNova reported Q1 2026 revenue of $362.3M (+14.3% YoY reported, +11.1% constant-currency), beatin
May 6, 2026
NEUTRAL
DEFA14A
2/10
LivaNova filed a definitive additional proxy soliciting material (DEFA14A) providing notice of its 2
Apr 29, 2026
BULLISH
8-K
7/10
LivaNova reported strong full-year 2025 results with double-digit revenue growth and improved margin
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (81% buy). Based on 16 analysts: 6 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$80.60 mean target
+2.7% upside
Hold (1.70)
$67.00 Low
$95.00 High
| Metric | Value |
|---|---|
| Current Price | $78.50 |
| Target Low | $67.00 |
| Target Mean | $80.60 |
| Target Median | $80.50 |
| Target High | $95.00 |
| # Analysts | 10 |
| Recommendation | Hold (1.70) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.09 | $1.06 | $1.13 | 3.9% | -0.1% | 4↑ 1↓ | $0.4B | 8.0% | 9 |
| Next Q 2026-09-30 |
$1.08 | $1.03 | $1.13 | -2.6% | -4.5% | 2↑ 5↓ | $0.4B | 6.3% | 9 |
| Current FY 2026-12-31 |
$4.25 | $4.23 | $4.26 | 8.9% | +0.1% | 8↑ 0↓ | $1.5B | 8.6% | 9 |
| Next FY 2027-12-31 |
$4.63 | $4.49 | $4.93 | 9.0% | -0.2% | 7↑ 1↓ | $1.6B | 7.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.091 | |
| 7d ago | $1.089 | +0.002 |
| 30d ago | $1.092 | -0.001 |
| 60d ago | $1.092 | -0.001 |
| 90d ago | $1.092 | -0.001 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 25, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 7, 2026 | Stifel | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| May 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Apr 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Mar 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Feb 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Jan 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 10, 2026
short_volume
Short Volume: LIVN — 84.8% short (0.6M / 0.7M)
Short: 600,662 | Exempt: 31,100 | TRF Vol: 708,499 | Short Ratio: 84.8% | Off-exchange volume (dark pool + OTC)
May 28, 2026
ftd
FTD: LIVN — 60,890 shares ($4.5M) failed to deliver
Settlement: 20260528, Price: $73.90, FTD Value: $4,499,771, LIVANOVA PLC SHS (GBR)
May 27, 2026
short_volume
Short Volume: LIVN — 81.4% short (0.5M / 0.6M)
Short: 455,136 | Exempt: 129,700 | TRF Vol: 558,961 | Short Ratio: 81.4% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: LIVN — 19,305 shares ($1.4M) failed to deliver
Settlement: 20260513, Price: $71.75, FTD Value: $1,385,133.75, LIVANOVA PLC SHS (GBR)
May 7, 2026
short_volume
Short Volume: LIVN — 61.4% short (0.4M / 0.7M)
Short: 447,973 | Exempt: 46,932 | TRF Vol: 729,351 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
LIVN Q1 2026 Earnings Before Market Open — 2026-05-06
May 6, 2026
short_volume
Short Volume: LIVN — 65.4% short (0.7M / 1.1M)
Short: 698,868 | Exempt: 0 | TRF Vol: 1,068,522 | Short Ratio: 65.4% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_interest
FTD: LIVN — 18,361 shares ($1.1M) failed to deliver
Settlement: 20260506, Price: $57.59, FTD Value: $1,057,409.99, LIVANOVA PLC SHS (GBR)
Apr 30, 2026
short_volume
Short Volume: LIVN — 90.9% short (0.5M / 0.6M)
Short: 514,386 | Exempt: 0 | TRF Vol: 566,135 | Short Ratio: 90.9% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_volume
Short Volume: LIVN — 71.5% short (0.4M / 0.6M)
Short: 396,756 | Exempt: 0 | TRF Vol: 555,092 | Short Ratio: 71.5% | Off-exchange volume (dark pool + OTC)
Feb 25, 2026
earnings_calendar
LIVN Q4 2025 Earnings Before Market Open — 2026-02-25